Drs. Granger, Goodman, and Pollack provide an introduction to the Factor XI hypothesis of hemostasis-sparing anticoagulation, explaining the unlinking of hemostasis and thrombosis in a modern conception of the coagulation cascade. They provide a brief overview of the development of Factor XI and Factor XIa inhibitors to date in multiple therapeutic areas, and then focus on stroke prevention in atrial fibrillation, a burgeoning indication in which too many patients remain unprotected from thromboembolic events because of risk or fear of bleeding. Finally, they introduce the ongoing Phase 3 LILAC TIMI 73 trial, which is comparing the monoclonal antibody Factor XI inhibitor abelacimab to placebo in patients with AF and moderate to high risk of stroke deemed unsuitable for currently available anticoagulants.
Cardiologists managing patients with AF who are unsuitable for conventional anticoagulation
Better understand current unmet needs in the provision of safe and effective stroke prevention for patients with atrial fibrillation
Introduction to the Factor XI inhibitors, a new class of anticoagulant with the potential to reduce bleeding risk
Review the types of patients who may be well suited for inclusion in the LILAC-TIMI 76 study
Learn about clinical trial sites in your region to which patients can be referred to determine eligibility
A Review of Anticoagulation Therapy: Challenges and Lessons Learned
Understanding Factor XI and Thrombosis
Clinical Trial Data, Including an Analysis of LILAC-TIMI 76: Efficacy and Safety
Interpreting Inclusion Criteria and Best Practices for Referring Patients to the Trial
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity.
Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
Faculty | Relationship Identified With: |
Christopher B. Granger, MD | Grants: Alnylam, Boehringer Ingelheim, Bristol Myers Squibb, FDA, Janssen, Lilly, Novartis, Pfizer, Philips, Roch Consulting: Abbvie, Abiomed, AlnylamPharmaceuticals, Anthos, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardionomic, Cadrenal, CeleCore Therapueutics, HengRui, Janssen, Medscape, Medtronic Inc., Merck, NIH, Novo Nordisk, Novartis, Pfizer, Philips , REATA, Roche, Veralox Stock or Stock Options: Tenac.io |
Shaun G. Goodman, MD | Research Grants and/or Speaker/Consulting Honoraria: Alnylam, Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, CYTE Ltd., Daiichi-Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, HLS Therapeutics, Idorsia, JAMP Pharma, Merck, Novartis, Novo Nordisk A/C, Pendopharm/Pharmascience, Pfizer, Regeneron, Roche, Sanofi, Servier, Tolmar Pharmaceuticals, Valeo Pharma Salary Support/Honoraria: Canadian Heart Failure Society, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, Jewish General Hospital\ CIUSSS Centre-Ouest-de-l'Ile-de-Montreal, New York University Clinical Coordinating Centre, PERFUSE Research Institute, Peter Munk Cardiac Centre Clinical Trials and Translation Unit, Ted Rogers Centre for Heart Research, TIMI Study Group (Brigham Health) |
Charles Pollack, MD
| Research Grants and/or Speaker/Consulting Honoraria: Anthos; AstraZeneca; Cayuga; Huyabio; Idorsia; Provepharm; VarmX |
Timothy Hayes, MD, PhD; Nicole McMenamin and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits TM.
AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours (Provider #P0491).
AcademicCME designates this continuing education activity for 0.50 CPE Contact Hours (0.05 CEUs) of continuing pharmacy education credit (UAN #JA4008190-0000-25-001-H01-P).
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Anthos Therapeutics.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Anthos Therapeutics do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606
Automated page speed optimizations for fast site performance